]>
IRCT20090905002417N21 IRCT 2019-07-07 Esfahan University of Medical Sciences Effect of Rosuvastatin in contrast induced nephropathy The effect of Rosuvastatin on the incidence of contrast nephropathy in patients with chronic renal failure receiving contrast 2018-01-21 anticipated 350 Complete https://irct.ir/trial/39751 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: simple randomization with random numbers, Blinding description: patients who are arrived in the study, the trained nurse who is directing patients into the study, investigator, data analyser. 2-3 Effect of Rosuvostatin in contrast induced nephropathy in chronic kidney disease. Intervention 1: Intervention group: 175 patients is entered in study that they have chronic kidney disease and their eGFR are 30-60mg/dL. one day before contrast administration, they eat 2 tablet Rosuvastatin, Abidi pharmaceutic, IRAN. in the day of contrast administration and one day after that, they receive one tablet the same as before. 48 hours after contrast administration they undergo laboratory examination. Intervention 2: Control group: 175 patients is entered in study that they have chronic kidney disease and their eGFR are 30-60mg/dL. one day before contrast administration, they eat 2 tablet (placebo) Rosuvastatin, Abidi pharmaceutic, IRAN. in the day of contrast administration and one day after that, they receive one tablet the same as before. 48 hours after contrast administration they undergo laboratory examination. Yes - There is a plan to make this available What will be shared: the shareable data contain points that will be published in the article. When: Starting 1 year after publication To whom: Available for academic investigators and industrial persons Conditions: for more information contact us with email. Where to obtain: contact with email How to obtain: maximum 1 year after sending your email we response you Comments:
public ّّFirouzeh Moeinzadeh
Sofe Ave. Isfahan
Esfahan Iran (Islamic Republic of) 8174675731 +98 31 3822 2267 fimoinzad@yahoo.com Esfahan University of Medical Sciences scientific Firouzeh Moeinzadeh
Sofe Avenue Isfahan
Isfahan Iran (Islamic Republic of) 8174675731 +98 31 3822 2267 fimoinzad@yahoo.com Esfahan University of Medical Sciences Iran (Islamic Republic of) absence of Statin use during past 3 months eGFR between 30 - 60 cc/min/1.73m2 not pregnant absence use of contrast during past 10 days absence use of Metformin 18 years 90 years Both Acute coronary syndrome history of allergy to contrast media death during 72 hours after receiving contrast media end stage renal disease N18.3 chronic kidney disease Treatment - Drugs Treatment - Drugs Intervention group: 175 patients is entered in study that they have chronic kidney disease and their eGFR are 30-60mg/dL. one day before contrast administration, they eat 2 tablet Rosuvastatin, Abidi pharmaceutic, IRAN. in the day of contrast administration and one day after that, they receive one tablet the same as before. 48 hours after contrast administration they undergo laboratory examination. Control group: 175 patients is entered in study that they have chronic kidney disease and their eGFR are 30-60mg/dL. one day before contrast administration, they eat 2 tablet (placebo) Rosuvastatin, Abidi pharmaceutic, IRAN. in the day of contrast administration and one day after that, they receive one tablet the same as before. 48 hours after contrast administration they undergo laboratory examination. Serum creatinin level. Timepoint: 48 hours after contrast media use. Method of measurement: autoanalyser. Esfahan University of Medical Sciences Approved 2017-05-22 Ethics committee of Isfahan University of Medical Sciences Hezar Jarib street Isfahan Isfehan Iran (Islamic Republic of)